AU2008316472A1 - Indoline compounds - Google Patents

Indoline compounds Download PDF

Info

Publication number
AU2008316472A1
AU2008316472A1 AU2008316472A AU2008316472A AU2008316472A1 AU 2008316472 A1 AU2008316472 A1 AU 2008316472A1 AU 2008316472 A AU2008316472 A AU 2008316472A AU 2008316472 A AU2008316472 A AU 2008316472A AU 2008316472 A1 AU2008316472 A1 AU 2008316472A1
Authority
AU
Australia
Prior art keywords
indol
dihydro
ethyl
disorders
acetamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008316472A
Other languages
English (en)
Inventor
Jose Falco
Antonio Guglietta
Albert Palomer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferrer Internacional SA
Original Assignee
Ferrer Internacional SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrer Internacional SA filed Critical Ferrer Internacional SA
Publication of AU2008316472A1 publication Critical patent/AU2008316472A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2008316472A 2007-10-25 2008-10-23 Indoline compounds Abandoned AU2008316472A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200702798A ES2331274B1 (es) 2007-10-25 2007-10-25 Compuesto de indolina.
ESP200702798 2007-10-25
PCT/EP2008/064389 WO2009053440A1 (en) 2007-10-25 2008-10-23 Indoline compounds

Publications (1)

Publication Number Publication Date
AU2008316472A1 true AU2008316472A1 (en) 2009-04-30

Family

ID=40219359

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008316472A Abandoned AU2008316472A1 (en) 2007-10-25 2008-10-23 Indoline compounds

Country Status (16)

Country Link
US (1) US20110112148A1 (cg-RX-API-DMAC7.html)
EP (1) EP2203423A1 (cg-RX-API-DMAC7.html)
JP (1) JP2011500763A (cg-RX-API-DMAC7.html)
KR (1) KR20100075518A (cg-RX-API-DMAC7.html)
CN (1) CN101878200A (cg-RX-API-DMAC7.html)
AR (1) AR069003A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008316472A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0818850A2 (cg-RX-API-DMAC7.html)
CA (1) CA2703453A1 (cg-RX-API-DMAC7.html)
CL (1) CL2008003139A1 (cg-RX-API-DMAC7.html)
ES (1) ES2331274B1 (cg-RX-API-DMAC7.html)
MX (1) MX2010004463A (cg-RX-API-DMAC7.html)
RU (1) RU2010120847A (cg-RX-API-DMAC7.html)
TW (1) TW200934760A (cg-RX-API-DMAC7.html)
UY (1) UY31423A1 (cg-RX-API-DMAC7.html)
WO (1) WO2009053440A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102942516B (zh) * 2012-11-05 2015-02-25 宁波大学 一种生物碱类化合物及其制备方法和应用
CN103044310B (zh) * 2013-01-18 2015-02-04 贵阳医学院 二氢吲哚-3-乙酸衍生物、其制备方法以及在药物中的应用
US12599584B2 (en) 2016-01-21 2026-04-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Indoline derivatives, compositions comprising them and uses thereof
AR121842A1 (es) * 2020-04-15 2022-07-13 Ache Laboratorios Farmaceuticos Sa Compuesto de benzimidazol para el tratamiento de trastornos metabólicos

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2680366B1 (fr) * 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
GB9326192D0 (en) 1993-12-22 1994-02-23 Glaxo Group Ltd Chemical compounds
CA2186412A1 (en) * 1995-10-31 1997-05-01 Katherine S. Takaki Ethylamino carbazole melatonergic agents

Also Published As

Publication number Publication date
EP2203423A1 (en) 2010-07-07
TW200934760A (en) 2009-08-16
RU2010120847A (ru) 2011-11-27
MX2010004463A (es) 2010-05-03
US20110112148A1 (en) 2011-05-12
ES2331274B1 (es) 2010-10-21
ES2331274A1 (es) 2009-12-28
CL2008003139A1 (es) 2009-03-06
AR069003A1 (es) 2009-12-23
KR20100075518A (ko) 2010-07-02
WO2009053440A1 (en) 2009-04-30
CA2703453A1 (en) 2009-04-30
CN101878200A (zh) 2010-11-03
JP2011500763A (ja) 2011-01-06
UY31423A1 (es) 2009-04-30
BRPI0818850A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
CN117440955A (zh) 具有食欲素-2受体激动剂活性的取代的酰胺大环化合物
MX2014012992A (es) Derivado de quinazolindiona.
RU2444515C2 (ru) Производное амида индазолакриловой кислоты
HU198014B (en) Process for producing antiarithmic sulfonamides and pharmaceutical compositions containing them
EP1724259A1 (en) 2,7-substituted 5-amino-4-hydroxy-8-(1h-indazol-5-yl)-octan amide derivatives and related compounds as renin inhibitors for the treatment of hypertension
RU2162470C2 (ru) 2,7-замещенные производные октагидропирроло[1,2-а]пиразина, способ лечения, фармацевтическая композиция, промежуточные соединения
US20110112148A1 (en) Indoline compounds
AU2009275918A1 (en) 1,6-dihydro-2H-3-oxa-6-aza-as-indacene compounds
US5498628A (en) Naphthamide derivatives
CZ292847B6 (cs) Derivát benzamidu, způsob jeho přípravy a použití, farmaceutická kompozice na jeho bázi a způsob její přípravy
CZ102896A3 (en) 4-indolylpiperazinyl derivatives
CA2317515A1 (en) Oxazole derivatives as serotonin-1a receptor agonists
WO2010145989A1 (en) 1-(2-alkyl-2,3-dihydro-benzofuran-4-yl)-pyrrolidin-3-ylamine acyl compounds
CA2703461A1 (en) Compounds of 2,3-dihydro-benzofuran
WO2009053443A2 (en) Indane compounds
EP2203422B1 (en) Phenylpyrrolidine compounds
CA3163938C (en) Tetrahydroisoquinoline compound as potassium channel modulator and preparation and application thereof
HK1145679A (en) Indoline compounds
Sparatore et al. 2-{4-[3-(4-Aryl/heteroaryl-1-piperazinyl) propoxy] phenyl}-2H-benzotriazoles and their N-oxides as ligands for serotonin and dopamine receptors
CA3163938A1 (en) Tetrahydroisoquinoline compound as potassium channel modulator and preparation and application thereof
HK1145327A (en) Compounds of 2,3-dihydro-benzofuran
HK1145680A (en) Phenylpyrrolidine compounds

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application